HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Erratum (v30,p1684) All Versions of this Article: dc06-1712v1 30/4/795    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vinik, A. I. Articles by Zhang, Q. Search for Related Content PubMed PubMed Citation Articles by Vinik, A. I. Articles by Zhang, Q. Social Bookmarking                What's this?

Adding Insulin Glargine Versus Rosiglitazone

Health-related quality-of-life impact in type 2 diabetes

¹ Strelitz Diabetes Research Institutes, Eastern Virginia Medical School, Norfolk, Virginia
² Department of Health Outcomes, Sanofi-Aventis U.S., Bridgewater, New Jersey

Address correspondence and reprint requests to Aaron I. Vinik, MD, PhD, Director, Strelitz Diabetes Research Institutes, Eastern Virginia Medical School, 855 W. Brambleton Ave., Norfolk, VA 23510. E-mail: vinikai{at}evms.edu

OBJECTIVE—We sought to assess health-related quality of life (HRQOL) in patients with type 2 diabetes treated with insulin glargine or rosiglitazone as add-on therapy to sulfonylurea plus metformin.

RESEARCH DESIGN AND METHODS—HRQOL was evaluated in 217 subjects uncontrolled with sulfonylurea plus metformin, enrolled in a 24-week, multicenter, randomized, open-label, parallel-group trial of add-on insulin glargine versus rosiglitazone. A 40-item, self-administered questionnaire at baseline and at weeks 2, 6, 12, 18, and 24 was given, including the 34-item Diabetes Symptom Checklist-Revised (DSC-R), a 5-item mental health scale from the 36-item Short-Form Health Survey (SF-36), and a single-item health rating from the SF-36. These assessments do not specify route of therapy.

RESULTS—Both treatment groups showed similar improvements in glycemic control from baseline to week 24 (change in A1C: –1.66% in the insulin glargine group, –1.51% in the rosiglitazone group, P = 0.1446). Both groups also showed improvement in HRQOL, although subjects treated with insulin glargine experienced significantly greater improvements compared with rosiglitazone in the DSC-R total symptom score (P = 0.005), total symptom distress score (P = 0.03), individual domain scores for mood symptoms (P = 0.007), ophthalmologic symptoms (P = 0.007), ophthalmologic distress (P = 0.013), fatigue distress (P = 0.033), and SF-36 perception of general health (P = 0.047).

CONCLUSIONS—Although addition of insulin glargine and rosiglitazone achieved comparable improvements in glycemic control, insulin glargine was associated with greater improvements in HRQOL, indicating that other factors (e.g., safety profile and nonglycemic actions) may further enhance HRQOL in patients with type 2 diabetes.

Abbreviations: DSC-R, Diabetes Symptom Checklist-Revised • FPG, fasting plasma glucose • HRQOL, health-related quality of life • QOL, quality of life • SF-36, 36-item Short-Form Health Survey • UKPDS, UK Prospective Diabetes Study

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Insulin Glargine vs. Rosiglitazone: Quality-of-Life Outcomes Journal Watch (General), May 3, 2007; 2007(503): 2 - 2. [Full Text]